Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Damien Basille (Amiens, France), Damien Basille, Charlotte Trouve, Nathalie Plouvier, Claire Andrejak, Vincent Jounieaux. Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia : A cohort study. Eur Respir J 2016; 48: Suppl. 60, 3330

Member's Comments

No comment yet.

Related content which might interest you: Influence of prior nonsteroidal anti-inflammatory steroidal drugs (NSAID) on the presentation and evolution of hospitalized community-acquired pneumonia Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia Year: 2018 Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia Source: Eur Respir J 2015; 46: 876-877 Year: 2015 Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia Source: Eur Respir J 2015; 46: 875-876 Year: 2015 Benefits of co-administration of macrolides and glucocorticosteroids in the treatment of severe community acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia? Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Relationship between the use of inhaled steroids and early outcomes in community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Pneumocystis pneumonia in the non-HIV population Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia? Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues Year: 2015 The mechanisms of antiinflammatory effect of mucolytic therapy Source: International Congress 2014 – Predictors Year: 2014 Effects of systemic steroids in patients with severe community-acquired pneumonia Source: Eur Respir J 2007; 30: 951-956 Year: 2007 Antipyretic effect of dexamethasone in community-acquired pneumonia Source: Eur Respir J 2015; 46: 570-573 Year: 2015 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Anti-inflammatory therapies in bronchiectasis Source: Eur Respir Mon 2011; 52: 223-238 Year: 2011 Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Study of antioxidant use in patients with asthma exacerbations Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Inhaled drugs as risk factors for community-acquired pneumonia Source: Eur Respir J 2010; 36: 1080-1087 Year: 2010